Orbitrap Illustration

Scientific Library

Access peer-reviewed scientific papers, application notes, technical guides, specification sheets, scientific posters, brochures, product support bulletins, webinars, and much more....

Please set up alerts based on your interests for notification of new content added by our scientists.

Remember, you must  register on the site and login to your account to see search results. 

Expand Results
Scientific Paper Orbitrap Fusion, Exactive Plus EMR PTM - Glycosylation, BIOPHARMACEUTICALS - ALL

Native mass spectrometry combined with enzymatic dissection unravels glycoform heterogeneity of biopharmaceuticals

Therese Wohlschlager 1,2, Kai Scheffler 2,3, Ines C. Forstenlehner 1,2,4, Wolfgang Skala 1,2, Stefan Senn 1,2, Eugen Damoc 5, Johann Holzmann 2,4 & Christian G. Huber 1,2

Nature Communications volume 9, Article number: 1713 (2018) doi:10.1038/s41467-018-04061-7

1 Department of Biosciences, Bioanalytical Research Labs, University of Salzburg, Hellbrunner Strasse 34, 5020 Salzburg, Austria. 2 Christian Doppler Laboratory for Innovative Tools for Biosimilar Characterization, University of Salzburg, Hellbrunner Strasse 34, 5020 Salzburg, Austria. 3 Thermo Fisher Scientific GmbH, Dornierstraße 4, 82110 Germering, Germany. 4 Technical Development Biosimilars, Global Drug Development, Novartis, Sandoz GmbH, Biochemiestrasse 10, 6250 Kundl, Austria. 5 Thermo Fisher Scientific GmbH, Hanna-Kunath-Strasse 11, 28199 Bremen, Germany.

Robust manufacturing processes resulting in consistent glycosylation are critical for the efficacy and safety of biopharmaceuticals. Information on glycosylation can be obtained by conventional bottom–up methods but is often limited to the glycan or glycopeptide level. Here, we apply…

Read more... Link to related website Email This Item

Number of Views